Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL‐1601D with US and European insulin aspart in healthy volunteers: A randomized, double‐blind, crossover, euglycaemic glucose clamp study

AIM: To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence (BE) of MYL‐1601D biosimilar with originator, NovoLog (Ref‐InsAsp‐US), and NovoRapid (Ref‐InsAsp‐EU). MATERIALS AND METHODS: This was a double‐blind, randomized, crossover study that enrolled 71 healthy subjects to rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Hövelmann, Ulrike, Raiter, Yaron, Chullikana, Anoop, Liu, Mark, Donnelly, Charles, Lawrence, Tracey, Sengupta, Nilanjan, CL, Gopu, Ranganna, Gopinath, Barve, Abhijit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292719/
https://www.ncbi.nlm.nih.gov/pubmed/34378861
http://dx.doi.org/10.1111/dom.14519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292719/
https://www.ncbi.nlm.nih.gov/pubmed/34378861
http://dx.doi.org/10.1111/dom.14519

Ejemplares similares